GHP Investment Advisors Inc. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 6.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,486 shares of the medical research company’s stock after purchasing an additional 1,572 shares during the period. GHP Investment Advisors Inc.’s holdings in Amgen were worth $6,903,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Talbot Financial LLC lifted its stake in shares of Amgen by 5.6% in the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company’s stock worth $11,153,000 after acquiring an additional 2,274 shares during the period. Swiss National Bank raised its holdings in Amgen by 0.3% during the third quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company’s stock worth $513,033,000 after purchasing an additional 5,500 shares in the last quarter. Asset Advisors Investment Management LLC lifted its position in Amgen by 9.0% in the third quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company’s stock worth $11,578,000 after purchasing an additional 2,954 shares during the period. Principal Financial Group Inc. boosted its stake in Amgen by 6.0% during the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company’s stock valued at $204,659,000 after purchasing an additional 35,785 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its position in shares of Amgen by 3.2% during the 3rd quarter. First Horizon Advisors Inc. now owns 60,769 shares of the medical research company’s stock valued at $19,581,000 after purchasing an additional 1,872 shares during the period. 76.50% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
AMGN has been the subject of several research analyst reports. Bank of America upped their price objective on Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a report on Thursday. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research note on Friday, January 24th. Leerink Partners cut their target price on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Finally, Wells Fargo & Company decreased their price target on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $314.83.
Amgen Stock Up 6.5 %
Shares of Amgen stock opened at $307.81 on Thursday. The firm has a market cap of $165.46 billion, a price-to-earnings ratio of 39.41, a P/E/G ratio of 2.87 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The stock has a 50-day simple moving average of $271.69 and a 200-day simple moving average of $303.55.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%. On average, equities research analysts expect that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.
Amgen Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.09%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is 115.24%.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- The How And Why of Investing in Oil Stocks
- Alphabet’s 8% Drop Might Be the Entry Opportunity of the Year
- Insider Trading – What You Need to Know
- Volatility is Back: 3 Must-Have Stocks to Weather the Storm
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- BigBear.ai: Can New Leadership and Deregulation Unlock Growth?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.